MA R K E T R E S E A R CH BR I E F I N G · 2 0 2 6 – 2 03 5
Peptide Synthesis Service Market Global Industry Analysis and Forecast (2026–2035) — GLP-1 demand is scaling a research service into a USD 30.0 Billion manufacturing industry
>4× expansion
USD 6.8B (2025) → USD 30.0B (2035)
$6.8B
$8.0B
$30.0B
15.8%
Market size, 2025
Estimated size, 2026
Forecast, 2035
CAGR, 2026–2035
Executive Summary
Market Share Leaders, 2025
A USD 22.0B absolute dollar opportunity opens
North America (region)
43%
between 2026 and 2035. GLP-1 driven GMP capacity, cyclic peptide
Custom Peptide Synthesis
47%
Solid-Phase Synthesis (SPPS)
68%
Pharmaceutical Companies
44%
discovery and conjugate chemistry drive the
structural shifts. North America leads (~43%); Asia-Pacific grows fastest at 19.3% CAGR.
Moderately consolidated: top five providers hold ~56% of validated GMP-SPPS capacity.
Industry Ecosystem 1 · Inputs
2 · Synthesis
3 · Quality
4 · End Users
Amino acids, reagents,
SPPS, LPPS, hybrid,
Purification, analytics,
Pharma, biotech,
equipment
enzymatic
GMP compliance
diagnostics, academia
Copyright © Next Move Strategy Consulting
01
MA R K E T S I Z E & S E G ME NT ATI O N
Revenue Quadruples to USD 30.0B by 2035 Global revenue forecast, USD Billion — expanding at a 15.8% CAGR (2026–2035)
+15.8% CAGR
30.00
2026 → 2035
25.87 22.34 19.29 16.66 14.39
8.00
6.80
2025
2026
9.26
2027
10.73
2028
12.42
2029
2030
2031
2032
2033
2034
2035
USD 22.0B
USD 2.45B
22.3% CAGR
Absolute dollar opportunity,
U.S. — dominant country, 2025
India — fastest-growing country
2026–2035
Segment Leadership vs. Momentum Segment
Largest share (2025)
Fastest growth (CAGR)
Service Type
Custom Synthesis — 47% ($3.2B)
GMP Manufacturing — 18.0%
Technology
Solid-Phase (SPPS) — 68% ($4.6B)
Enzymatic — 26.2%
Peptide Type
Linear — 60% ($4.1B)
Cyclic — 19.8%
Modification
Unmodified — 44% ($3.0B)
Conjugated — 21.3%
Purity Grade
Research Grade — 50% ($3.4B)
GMP Grade — 21.7%
Production Scale
Milligram — 38% ($2.6B)
Large-Scale — 24.7%
End User
Pharma Companies — 44% ($3.0B)
Animal Health — 23.3%
Copyright © Next Move Strategy Consulting
02
G R O W T H D R I V E R S & O P P O R T U N I T IE S
GLP-1 Demand Anchors a MultiEngine Growth Cycle Impact on market CAGR (2026–2035): six drivers lift growth; constrained GMP capacity is the main brake GLP-1 peptide therapeutic demand
+3.4%
Metabolic & oncology peptide pipeline
+2.6%
GMP-scale capacity investment by CDMOs
+2.2%
Cyclic & conjugated modality adoption
+1.8%
Regional capacity diversification
+1.3%
Custom peptide library demand
+0.9%
Constrained validated GMP-SPPS capacity
−1.6%
High reactor & purification capex
−1.1%
Consolidation of independent providers
−0.7%
Complex synthesis yield & purification
−0.5%
Regional Growth Opportunity Map 1 · North America ~43% share (USD 2.9B, 2025); U.S. at USD 2.45B
2 · Asia-Pacific
3
1
Highest regional CAGR 19.3%; India
4
2
22.3%
3 · Europe Bachem Building K; Corden ~EUR 1B expansion
4
4 · Middle East & LatAm Emerging GMP CDMOs for dual-sourcing
High-Growth Segments (CAGR 2026–2035)
26.2%
24.7%
23.3%
21.7%
21.3%
Enzymatic synthesis
Large-scale production
Animal health end users
GMP purity grade
Conjugated peptides
Whitespace for investors: enzymatic green-chemistry platforms · integrated peptide-drug conjugate capability · GMP-certified regional CDMOs
Copyright © Next Move Strategy Consulting
03
CO MP E T I T I V E S CE N A R IO
Validated Capacity Is the New Competitive Moat A moderately consolidated market where scale players and specialists compete on capacity and chemistry
~56%
~36%
USD 1.81B
GMP-SPPS capacity held by top
of manufacturers ran above 80%
Samsung Biologics–PolyPeptide
five providers
utilization (2025)
deal (2026)
Integrated process development & manufacturing →
Competitive Positioning Matrix
Key Strategic Moves LARGE-SCALE GMP MANUFACTURERS
Aug 2026 — CordenPharma completes
M&A
AmbioPharm acquisition (U.S. & Shanghai)
Bachem
PolyPeptide for ~USD 1.81B EXP
Corden Pharma JPT
2026 — Samsung Biologics to acquire
M&A
Apr 2026 — Bachem inaugurates Building K, Bubendorf
Samsung / PolyPeptide
SK pharmteco
EXP
Oct 2025 — SK pharmteco USD 6.1M cGMP kilo-scale SPPS, California
EXP
SK pharmteco USD 260M Sejong facility, eight production trains
GenScript
EXP
Corden Pharma ~EUR 1B peptide expansion, Basel region
Biomatik AnaSpec
SPECIALIZED RESEARCH-GRADE Validated commercial GMP capacity → (qualitative)
Key Market Players Bachem Holding AG
PolyPeptide Group AG
Corden Pharma Intl.
WuXi AppTec
GenScript Biotech
Thermo Fisher Scientific
Ajinomoto Bio-Pharma
SK pharmteco
ScinoPharm Taiwan
CPC Scientific
Neuland Laboratories
GL Biochem (Shanghai)
BCN Peptides
AnaSpec, Inc.
JPT Peptide Tech.
Bio-Synthesis, Inc.
ProteoGenix
AAPPTec LLC
Biomatik Corporation
LifeTein, LLC
Winning playbook: secure validated large-scale GMP capacity · automate SPPS · build conjugate & enzymatic chemistry · enter via M&A
Copyright © Next Move Strategy Consulting
04
L E T ' S CO N N E CT
Thank You Connect with our analysts for in-depth insights and strategic guidance on the Peptide Synthesis Service Market
Contact Us W T @
Inside the Full Report
Official Websitewww.nextm
▸ Forecasts across 7 segmentation axes, 2026–
sc.com
2035
Contact Number+1
▸ Company-level revenue & project-volume
857 758 5017
benchmarking ▸ Synthesis technology scalability assessment
Emailinfo@nextmsc
▸ Pipeline-driven end-user demand analysis
.com
Click here for the complete report → Follow Us gen-dedup-715139c1047dc50fc11e5ba8a5e8448d.png
gen-dedup-a33c1d6ec6986994cdb6d06bff72aa8e.png
gen-dedup-af43e746accf3f78490ae3e6600388bf.png
YouTube
gen-dedup-8b664938785682eb80c49ba39d9d2e85.png
gen-dedup-ad7063d46eff26f2c1039a235c8d1328.png
Peptide Synthesis Service Market Global Industry Analysis and Forecast (2026–2035)
Copyright © Next Move Strategy Consulting
05